A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Biology & Therapy

• Publication date

  2016-01-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/15384047.2015.1121344PMID 26671532PMCID PMC4848005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus

  2015cited by this paper
• Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2

  2014cited by this paper
• Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding

  2014cited by this paper
• Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth.

  2014cited by this paper
• Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer

  2014cited by this paper
• Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

  2014cited by this paper
• Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma

  2014cited by this paper
• In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells

  2014cited by this paper
• Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

  2014cited by this paper
• VEGFA and tumour angiogenesis

  2013cited by this paper
• Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor

  2013cited by this paper
• Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth

  2013cited by this paper
• The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell

  2013cited by this paper
• The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways.

  2013cited by this paper
• Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth

  2012cited by this paper
• The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

  2012cited by this paper
• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  2011cited by this paper
• Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

  2011influential reference
• Vascular endothelial growth factor receptor-2 in breast cancer.

  2010cited by this paper
• Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

  2010cited by this paper
• Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection.

  2010cited by this paper
• The PI3K pathway as drug target in human cancer.

  2010cited by this paper
• Significance of VEGF and microvascular density in gastric carcinoma.

  2009cited by this paper
• VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2009cited by this paper
• Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

  2009cited by this paper
• Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

  2009cited by this paper
• ErbB receptors: from oncogenes to targeted cancer therapies.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

  2006cited by this paper
• Epidermal growth factor receptor (EGFR)–related protein inhibits multiple members of the EGFR family in colon and breast cancer cells

  2005cited by this paper
• Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

  2005cited by this paper
• Angiogenesis and lung cancer: prognostic and therapeutic implications.

  2005cited by this paper
• HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells

  2005cited by this paper
• A comprehensive pathway map of epidermal growth factor receptor signaling

  2005cited by this paper
• Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

  2004cited by this paper
• Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3.

  2004cited by this paper
• Review of epidermal growth factor receptor biology.

  2004cited by this paper
• Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38

  2004cited by this paper
• Angiogenesis and apoptosis.

  2003cited by this paper
• Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization

  1999cited by this paper
• Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor

  1994cited by this paper
• Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.

  1987cited by this paper

• Comparative multi-pathway inhibition of breast cancer by micro-and nano-formulated Curcumin

  2026cites this paper
• Physicochemical and biological characterization of a bispecific antibody in a CrossMab/KIH format that targets EGFR and VEGF-A

  2025cites this paper
• Molecular mechanisms and clinical significance of perineural invasion in malignancies: the pivotal role of tumor-associated Schwann cells in cancer progression and metastasis

  2025cites this paper
• Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis

  2025cites this paper
• Gene expression profiles of some prognostic markers in a human breast cell line (MCF7) exposed to Curcumin nanoparticles and nanocapsules

  2022influential citation
• Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

  2021cites this paper
• A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action

  2021cites this paper
• Bispecific Antibodies: Progress and Application

  2020cites this paper
• Artemisinin and its derivatives: a promising cancer therapy

  2020cites this paper
• Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.

  2019cites this paper
• Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.

  2017cites this paper
• Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물

  2017cites this paper
• Recent advances of bispecific antibodies in solid tumors

  2017cites this paper